8.18
Schlusskurs vom Vortag:
$8.33
Offen:
$8.29
24-Stunden-Volumen:
184.99K
Relative Volume:
0.50
Marktkapitalisierung:
$482.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.2168
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+8.63%
1M Leistung:
+3.28%
6M Leistung:
-22.46%
1J Leistung:
-58.92%
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CGEM
Cullinan Therapeutics Inc
|
8.18 | 491.59M | 0 | -153.16M | -134.48M | -3.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-11 | Fortgesetzt | Stifel | Buy |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-05-01 | Eingeleitet | Stifel | Buy |
2024-04-15 | Eingeleitet | William Blair | Outperform |
2024-02-15 | Eingeleitet | Wedbush | Outperform |
2023-06-15 | Eingeleitet | TD Cowen | Outperform |
2022-11-21 | Eingeleitet | BTIG Research | Buy |
2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
What is the dividend policy of Cullinan Therapeutics Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com
How Efficient Is Cullinan Therapeutics Inc. at Controlling Operating CostsFree Investment Portfolio Suggestions - Newser
What are analysts’ price targets for Cullinan Therapeutics Inc. in the next 12 monthsMaximize portfolio growth with expert advice - jammulinksnews.com
Is Cullinan Therapeutics Inc. stock overvalued or undervaluedInvest smarter with daily trading signals - jammulinksnews.com
How Cullinan Therapeutics Inc. stock performs during market volatilitySafe and Smart Investment Picks - Newser
What analysts say about Cullinan Therapeutics Inc. stockBreakneck growth rates - PrintWeekIndia
When is the best time to buy Cullinan Therapeutics Inc. stockFree Stock Chart Pattern Guide - jammulinksnews.com
What drives Cullinan Therapeutics Inc. stock priceSignificant capital appreciation - PrintWeekIndia
Cullinan Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com
Is Cullinan Therapeutics Inc. a good long term investmentUnbelievable profit margins - Autocar Professional
Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan
Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Disc Medicine Appoints Nadim Ahmed To Board - citybiz
Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times
We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener
Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
AHMED NADIM | President and CEO |
Feb 25 '25 |
Sale |
8.53 |
12,529 |
106,872 |
430,621 |
Michaelson Jennifer | Chief Scientific Officer |
Feb 25 '25 |
Sale |
8.53 |
3,756 |
32,039 |
142,004 |
SUMER JACQUELYN L | Chief Legal Officer |
Feb 25 '25 |
Sale |
8.53 |
3,756 |
32,039 |
136,895 |
Michaelson Jennifer | Chief Scientific Officer |
Jan 06 '25 |
Sale |
12.51 |
4,000 |
50,040 |
95,760 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):